Podcasts about Combination

The Bishop Score was originally developed in 1964 by Dr. Edward Bishop and remains the central assessment tool for determining the appropriateness of cervical ripening for labor induction. We have covered pharmacologic and mechanical methods of cervical ripening for labor induction many times in prior episodes. Ut now, in July 2025, there will be a new clinical practice guideline (#9) from the ACOG which has some notable items. Does the ACOG recognize COMBINATION mechanical and pharmacologic agents for cervical ripening for labor induction? What about outpatient cervical ripening? What are the recommended protocols for oral and vaginal prostaglandins? Listen in for details.

Sign up to Easy Ayurveda Video Classes by clicking the link belowhttps://www.easyayurveda.com/video-classes/Video Course: “Ayurvedic food and Nutrition”https://www.easyayurveda.com/nutrition/Buy Tridosha Made Easy Bookhttps://www.easyayurveda.com/tridosha-made-easy-3/Buy Tridosha Made Easy Book in Spanish LanguageEl corazón de los doshas: Nuevo librohttps://www.easyayurveda.com/el-corazon-de-los-doshas/Click to know more about Easy Ayurveda Hospitalhttps://www.easyayurveda.com/hospital/Buy our new course on Marma Therapy Part 1https://www.easyayurveda.com/marma1Buy our new course on Marma Therapy Part 1Subscribe to Easy Ayurveda Video Classes https://www.easyayurveda.com/video-classes/Subscribe to our free Easy Ayurveda newsletter here (you can unsubscribe and stop them anytime) -  https://forms.aweber.com/form/58/2129766958.htm Buy our course on diabetes reversal, powered by Madhavbaug https://www.easyayurveda.com/diabetes Buy our online video course on Treatment of cardiac disorders with Ayurveda https://www.easyayurveda.com/heartMaster ECG in one week. Sign up for video course https://www.easyayurveda.com/ecgContact Dr. MB Gururaja BAMS MD (Ayu)https://www.easyayurveda.com/gururaja  Contact Dr. Raghuram YS BAMS MD (Ayu)https://www.easyayurveda.com/raghuram Buy Easy Ayurveda Ebooks https://www.easyayurveda.com/my-book Buy Easy Ayurveda Printed Books https://www.easyayurveda.com/books/

What's on Craigslist? 6-16-2025 …Gay Man seeks Straight Woman for Family Picnic …Woman Seeks Man to Marry Immediately …Woman seeks Woman (Vomiting Okay) …It's a Combination, Brass Knuckles-Jesus/Taco Holder/Butt Plug

Dr. Casey Grover explores the history, neuroscience, and treatment approaches for methamphetamine use disorder, highlighting how methamphetamine releases more dopamine than any other known substance.• Methamphetamine was widely used during World War II by German, Japanese, and Allied forces to enhance performance• Modern meth production shifted from ephedra to P2P method, creating cheaper, more potent meth with worse psychiatric effects• Meth causes dopamine release up to 1,400 ng/dL of dopamine compared to cocaine (400), sex (200), and food (150), severely damaging reward centers• Many methamphetamine users have undiagnosed ADHD and are inadvertently self-medicating• Effective medications include bupropion, topiramate, atomoxetine, viloxazine, guanfacine, and mirtazapine• Contingency management (reward-based incentives) shows significant efficacy for methamphetamine addiction treatment• Combination therapies using bupropion with naltrexone show promise for reducing meth use• Treating underlying mental health conditions and providing housing/social support remains essential for recoveryTo contact Dr. Grover: ammadeeasy@fastmail.com

The side topic today for the 94 WIP Morning Show: what's the best combination of TV and movie role for example, Michael J. Fox as Marty McFly in Back to the Future as well as Alex P Keaton in Family Ties.

If you've ever wondered what a combination product is—or how to explain it—this video breaks it down clearly and simply. This is a non-technical, high-level explanation of what a combination product is. It's meant for anyone who works in or around pharma, medtech, or biotech and wants a clear, shareable reference—without getting into detailed regulatory definitions or region-specific nuances.I'm Subhi Saadeh, and I've spent my career in drug-device combination products. In this short reference video, I walk through:- What defines a combination product- Two key factors: primary mode of action and how components are combined- The difference between drug-led and device-led products- Examples of single-entity, co-packaged, and cross-labeled products00:00 Introduction to Drug Device Combination Products00:31 Defining Combination Products00:54 Philosophical Factors of Combination Products01:10 Drug-Led Combination Products01:51 Device-Led Combination Products02:32 Combination Configurations03:50 Summary and ConclusionAdditional Resources: - 21 CFR Part 4 FDA regulation on Current Good Manufacturing Practice (CGMP) requirements for combination products https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-4- FDA Guidance: Current Good Manufacturing Practice Requirements for Combination Productshttps://www.fda.gov/media/90652/download- FDA Combination Products Overview Page https://www.fda.gov/combination-products- 21 CFR Part 3 Regulations on combination product classification and primary mode of action (PMOA) https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-3- EU MDR Article 117 Requirements for drug-device combinations under the European Medical Device Regulation (Regulation (EU) 2017/745) https://health.ec.europa.eu/system/files/2021-10/md_mdr_2017-745_en_0.pdfSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

The Combination of Thomasina Petrus singing in front of the Selby Avenue Brass Band has been very well received. Catch this pairing in a comfortable listening situation, Crooners Supper Club in Fridley, Friday evening June 13 from 8 till 9:30. The leader of the Selby Avenue Brass Band is Tom Wells. Tom and Thomasina met with Phil Nusbaum to talk about the show, and first, Tom talked about the quality of the ensemble playing on a piece called Selby Strut.

This week on The Game Marks Podcast we are playing Fire Pro Wrestling Combination Tag.  How does the first ever Fire Pro Wrestling game hold up!?Please subscribe and leave a review for this podcast on Apple Podcast and Spotify and follow us on all forms of social media @gamemarkspod.Join George Feis & Johnny Clash each week as they do a #DeepDive into the good, the bad & the awesome of wrestling video games. Do your favorite games stand the test of time or are you playing them with nostalgia goggles? New episodes every other Monday!SponsorsMad Cat Beard Care: madcatbeardcare.com GAMEMARKS for 15% offMerch: podxchange.shopPro Wrestling Tees: prowrestlingtees.com/gamemarkspodTee Public: teepublic.com/user/gamemarkspodWWE Shop: wwe-shop.sjv.io/Qj05r3

In this episode, the guys discuss who they'd take to the bar, followed by a deep dive into the recent House vs. NCAA settlement and its implications for college sports. The conversation shifts to the impact of NIL deals on player recruitment and team dynamics. Once they've settled that once and for all, they jump to the seriously impressive play surrounding the Stanley Cup and NBA Finals. You have to watch these two finals if you're a fan of sport.They jump into the introduction of Supio, a new AI platform for plaintiff law firms. Supio turns case documents into critical insights with the power of AI to help firms work smarter, settle bigger and win more in court.They celebrate Coco Gauff's rise in women's tennis, marking her as a significant figure in the sport. In this conversation, the hosts discuss various themes in sports, focusing on women's tennis rivalries, the current state of men's American tennis (while wondering where the American male tennis champions have all gone), and the impact of coaching changes in the NBA and NHL. Assembly Software is a huge part of how the guys keep this show going. It's known for its leading case management product, TrialWorks, and its cloud-based solution, Neos. Neos allows law firms to access everything on the road and now features an AI program to enhance efficiency in tasks like drafting letters. Check out AssemblySoftware.com for more information.Last, they go on a mission to figure out what is in the minds of the Pittsburgh Steelers' management, and examine their quarterback "situation". They preview the US Open golf tournament, highlight the excitement of the College World Series, and address fan behavior in tennis matches.And of course the show would not be complete without Injury Board, an exclusive networking and marketing firm that connects and refers cases among the best plaintiffs' lawyers in the country. If you're a leader in your community and at the bar, consider checking out InjuryBoard.org for membership and referral opportunities.And If you're looking for a company to develop your website and digital marketing, Digital Law Marketing offers exclusive regional partnerships, unlike other companies that might prioritize marketing competitors. Their proven results have led to significant increases in organic originations. Go to DigitalLawMarketing.com for details.

Despite a bonus point win over Northampton on the final day, Gloucester missed out on the playoffs by 2 points - finishing 5th overall. We discuss the game and Snowy provides his Season Review (we all do the same over the coming weeks). We also discuss the Combination Cup finals day; the results and the games but also the unfortunate incident involving Longlevens and Matson 'supporters'. Finally we chat about the recently announced plans for an alternative R360 competition headed up by Mike Tindall and former Bath DOR Stuart Hooper.Ed PriceJames Eastwood (Snowy)Jim HarleyCherry Jam is proud to be sponsored by PGT LLP

The principal theme of this podcast episode centres on the notion that mere job performance is insufficient for career advancement. I engage in a dialogue with Andrea Wasserman, founder of Executive Express, who elucidates the invisible rules that govern professional progression, particularly for new graduates. Andrea emphasizes the critical importance of communication and executive presence, asserting that individuals must actively showcase their achievements to cultivate recognition in increasingly competitive environments. Furthermore, we explore the concept of "style flexing," which entails adapting one's approach based on the dynamics of the workplace. This conversation serves as a vital resource for listeners seeking to enhance their influence and navigate the complexities of career development effectively.Links referenced in this episode:theexecutiveexpress.comlinkedin.com/in/andreawassermaninstagram.com/theexecutiveexpresstiktok.com/@theexecutiveexpresssubstack.com/@theexecutiveexpressWant help creating your own podcast? Visit us at podjunction.com or reach out to Sadaf directly on LinkedIn: https://www.linkedin.com/in/sadafbeynon/

Buku How to Calm Your Mind https://www.periplus.com/p/9781035001996 Credit: ⁠@dipidiffofficial |

Hour 1 of the Tuesday Bob Rose Show, with the latest on lefty media outrage over the terror attack in Colorado and false report of violence at Gaza food distributions. Former DOJ official Andrew McCabe is caught again on the wrong side of facts, as CNN's disinformation coverage tanks the network's ratings. Plus the morning's breaking news for 6-3-25

Accuweather meteorologist Jeff Nordeen joins Chris and Amy as the region's air quality is being impacted this week.

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focusing on the combination of tafasitamab and lenalidomide. He highlights how this immunotherapy regimen, targeting CD19, has shown promising efficacy, with a high overall response rate and sustained complete responses in some patients. Salles also addresses real-world data, the regimen's tolerability, and its positioning in the treatment sequence, particularly for patients who are not candidates for CAR T-cell therapy. Lastly, he emphasizes the importance of tailoring treatment strategies based on patient characteristics and emerging therapies. Hosted on Acast. See acast.com/privacy for more information.

A recent study in mice explored how a combination of two supplements, lactoferrin and creatine, might help with age-related muscle loss, a condition called sarcopenia. Scientists induced sarcopenia in mice, causing their muscle mass and function to decline. For 8 weeks, these mice were given lactoferrin, creatine, or a mixture of both. The results were promising: the group of mice receiving both lactoferrin and creatine showed the most significant improvements. For example, the lean body content in the sarcopenia model group dropped to around 47-48%, while the group receiving the combination treatment saw their lean body content increase to about 51-52%, bringing them above the levels of the healthy control group (around 50%). In terms of muscle function, the combination group's endurance on a treadmill test was approximately 1200 seconds, a significant improvement compared to the sarcopenia model group (around 600 seconds) and even surpassing the healthy control group (around 900 seconds). Their grip strength also increased to roughly 180g with the combination, compared to about 130g in the model group and 150g in controls. These findings suggest that combining lactoferrin and creatine could be a beneficial nutritional strategy to combat muscle decay associated with aging, potentially by improving how muscles use energy and build protein. 3. Disclaimers:• "This information is for educational purposes only and should not be interpreted as medical advice."• "The study discussed was conducted on mice. Further research is needed to confirm these findings in humans."• "Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, especially if you have a medical condition or are taking medications."• "This Channel does not provide medical advice."#Sarcopenia #MuscleHealth #Lactoferrin #Creatine #AgingWellWu W, Guo X, Qu T, Huang Y, Tao J, He J, Wang X, Luo J, An P, Zhu Y, et al. The Combination of Lactoferrin and Creatine Ameliorates Muscle Decay in a Sarcopenia Murine Model. Nutrients. 2024; 16(12):1958. https://doi.org/10.3390/nu16121958Sarcopenia, creatine, lactoferrin, muscle mass, muscle function, aging, muscle decay, D-galactose, C57BL/6 mice, muscle strength, endurance, grip strength, lean body mass, nutritional intervention, muscle protein synthesis, energy metabolism, myogenic factors, RNA-seq, mTOR signaling, PI3K-Akt signaling, longevity regulating pathway, muscle atrophy, animal model, skeletal muscle, nutritional supplements

Marcus and Corey What You Know 'Bout That trivia game for Thursday May 15th, 2025.

• Intro• Xbox-Branded ROG Ally Leaks• SteamOS Game Verification Announced• The BACKLOG• Nintendo Gives Themselves Permission to Brick Your Switch• Switch 2 May Be Recording Your Audio and Voice Chats• Nintendo Estimates 15 Million Switch 2 Consoles Sold• 2025 Video Game Hall of Fame Inductees• Palworld Confirms Changes Due to Nintendo Lawsuit• Mafia: The Old Country Trailer and Release Details• Indiana Jones Now Steam Deck Verified• GTA VI Trailer a Combination of Cutscene and Gameplay• TWEET OF THE WEEK• Q&AOriginally streamed on May 13, 2025

https://youtu.be/rADiqnrhgrk Adam Coughlin, Co-founder, CMO, and Managing Partner of York IE, is on a mission to help startups beat the odds by building strong, capital-efficient brands that resonate with their markets. We explore Adam's Drumbeat Marketing Framework:Messaging & Positioning, Develop Unique Point of View, Execution, and Scorekeeping.He shares why brand consistency beats shiny-object syndrome, how vertical AI is redefining SaaS, and why startups need to balance storytelling with measurable impact. Adam also explains how to foster entrepreneurial thinking early and why founders must lead with a deep sense of purpose. --- Run Through Walls with Adam Coughlin Good day, dear listeners, Steve Preda here with the Management Blueprint Podcast. And my guest today is Adam Coughlin, co-founder, CMO and managing partner of York IE, where he works with startups on foundational messaging, content, communications, go-to-market strategy, website and digital marketing, revenue operations, and corporate storytelling. Welcome to the show, Adam. Yeah, thanks for having me, Steve. Appreciate it. Yeah, you guys are really a full-service shop. You do almost everything. So tell me, how are you guys unique, and what is it that makes you a superior solution for people? Yeah, absolutely. So the founding team of York IE, we all work together at a company called Dine here in New Hampshire that did the domain name system. And we built that company to about a hundred million of annual recurring revenue, got acquired by Oracle. While we were inside of Oracle, we kind of reflected on the growth journey that we took at Dine. And we felt that a lot of the legacy institutions that we turned to for growth help, whether that was our investors, our advisors, our vendors, they were operating out of antiquated models so that were really good for them, but not necessarily for us as the operators. And so that's what we wanted to disrupt. So in 2019, we launched York IE. We are an advisory and investment firm. So we help technology companies grow. We do that through investing in early stage exclusively B2B software companies. And then because we were operators, we also built a strategic advisory firm that does strategy and execution across the functional areas of R&D, go to market and G&A. Because we feel like we want to roll up our sleeves and help companies be successful.Share on X Yeah. So you're basically investing companies that advise them, help to improve them, and some you just advise them and don't invest. So it's a combination. Combination. Exactly. Right. And I think in addition to the advise, it's really important to get across that we do the execution because that is where companies need help. Especially early stage companies. A lot of those teams are small, they're dynamic, they have a good strategy, they just need help and take some things off their plates and we're there to help them with that. Sounds great. So that leads to my question. What is your personal “Why” and how are you manifesting it in your business? Yeah, absolutely. I think this is a great question. And my personal “Why” is I love entrepreneurs. I think that they are both visionary and builders and that they are pursuing their dreams in the effort to create something and build something that makes the world better. And I think that if they build good companies, then they hire good employees. Good companies have impacts on communities. Good companies build wealth.Share on X But unfortunately, the numbers are stacked against them. A large majority of startups fail, and I don't think that needs to be the case. And that's what I want to try to impact. If we can lower those numbers a little bit and help more founders and entrepreneurs succeed, then we're going to have a really positive impact on things because of all the good things that come from that success. Yeah, well, I couldn't resonate more with that.

Andy Smith, a heavy drinker all his life, everything fell apart for Andy as a 50 year old father of three. Redemption came from a very strange place! A Michael Jackson song started a journey of self-discovery that led him to get on his bike for charity - riding up Mt Everest, the course of the Tour de France and across the Arctic Circle. Andy now helps others, and speaks regularly on what his sobriety journey has taught him, and how it prepared him to push beyond his own self-imposed limitations.Website - https://www.soberinseven.com/LinkedIn - https://www.linkedin.com/in/thatandysmithFacebook - https://www.facebook.com/soberinsevenTwitter - https://twitter.com/soberinsevenYouTube - https://www.youtube.com/c/SoberinSevenInstagram - https://www.instagram.com/soberinsevenMaster of Your Crafts is a captivating podcast featuring conversations with individuals who have dedicated themselves to mastering their craft. Whether it's a gift, talent or skill that comes naturally to them, these individuals have taken ownership and honed their abilities to perfection. Through deep conversation, we delve into their inner dialogue, actions and life circumstances offering words of wisdom to empower and guide you on a journey to becoming the master of your own craft.For more information, visit our website https://masterofyourcrafts.com and Bright Shining Light Website: https://brightshininglight.comStay connected with us:- Facebook: https://www.facebook.com/masterofyourcrafts- Instagram: https://www.instagram.com/MasterOfYourCrafts/- Spotify: https://open.spotify.com/show/1M0vp9HoK7kkP1w4ij7PJd?si=7d383a92b93b4e2c- ApplePodcast: https://podcasts.apple.com/ca/podcast/master-of-your-crafts/id1512818795- Amazon Music: https://music.amazon.ca/podcasts/b15079de-bc6a-487c-b8f8-faca73d0f685/master-of-your-crafts- Google Play: https://podcasts.google.com/feed/aHR0...

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

(4/30/2025-5/6/2025) Combination order. Tune in.#applepodcasts⁠ ⁠#spotifypodcasts⁠ ⁠#youtube #amazon⁠ ⁠#patreon⁠patreon.com/isaiahnews

Ashley has been seeing this girl for a little bit now... but Ashley was a little taken back when she said she was going to the grocery store to pick up a few of these items...

Ashley has been seeing this girl for a little bit now... but Ashley was a little taken back when she said she was going to the grocery store to pick up a few of these items... See omnystudio.com/listener for privacy information.

One of Fort Collin's newest bars combines the bar experience with vinyl records, join Katie Heffernan on a deep dive into the business for today's feature story, Institutes within CSU offers new data to the public on forest management, Former home of Rams football Hughes Stadium faces an uncertain future as the community disagrees on the best way to use the land

Contributor: Aaron Lessen, MD Educational Pearls: What is a Rescue Inhaler? A rescue inhaler is a medication for people with asthma to quickly reverse the symptoms of an asthma attack. Historically albuterol (Short Acting Beta Agonist (SABA)) monotherapy has been the mainstay rescue inhaler. This is because albuterol works fast and is relatively cheap. What are Combination Rescue Inhalers? Combination rescue inhalers contain a fast-acting bronchodilator as well as an inhaled corticosteroid (ICS) The steroid helps to reduce some of the chronic airway inflammation that is worsening the asthma attack and can help to prevent future attacks Examples include budesonide-formoterol and albuterol-budesonide Global Initiative for Asthma (GINA), states that combination therapy is now the preferred reliever for adults and adolescents with mild asthma What are the drawbacks of Combination Rescue Inhalers? These inhalers are generally more expensive than just using a SABA inhaler which can be a barrier for some people Improper use can also lead to conditions like thrush due to the addition of the steroid References Krings JG, Beasley R. The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today. J Allergy Clin Immunol Pract. 2024 Apr;12(4):870-879. doi: 10.1016/j.jaip.2024.01.011. Epub 2024 Jan 17. PMID: 38237858; PMCID: PMC10999356. Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15. PMID: 35569035. Summarized by Jeffrey Olson, MS3 | Edited by Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://auau.auanet.org/node/42822 At the conclusion of this CME activity, participants will be able to: 1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer. 2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy. 3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes. 4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing. 5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination. ACKOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Merck & Co., Inc.

GraphBI: Expanding Analytics to All Data Through the Combination of GenAI, Graph, & Visual Analytics // MLOps Podcast #310 with Paco Nathan, Principal DevRel Engineer at Senzing & Weidong Yang, CEO of Kineviz.Join the Community: https://go.mlops.community/YTJoinIn Get the newsletter: https://go.mlops.community/YTNewsletter // AbstractExisting BI and big data solutions depend largely on structured data, which makes up only about 20% of all available information, leaving the vast majority untapped. In this talk, we introduce GraphBI, which aims to address this challenge by combining GenAI, graph technology, and visual analytics to unlock the full potential of enterprise data.Recent technologies like RAG (Retrieval-Augmented Generation) and GraphRAG leverage GenAI for tasks such as summarization and Q&A, but they often function as black boxes, making verification challenging. In contrast, GraphBI uses GenAI for data pre-processing—converting unstructured data into a graph-based format—enabling a transparent, step-by-step analytics process that ensures reliability.We will walk through the GraphBI workflow, exploring best practices and challenges in each step of the process: managing both structured and unstructured data, data pre-processing with GenAI, iterative analytics using a BI-focused graph grammar, and final insight presentation. This approach uniquely surfaces business insights by effectively incorporating all types of data.// BioPaco NathanPaco Nathan is a "player/coach" who excels in data science, machine learning, and natural language, with 40 years of industry experience. He leads DevRel for the Entity Resolved Knowledge Graph practice area at Senzing.com and advises Argilla.io, Kurve.ai, KungFu.ai, and DataSpartan.co.uk, and is lead committer for the pytextrank​ and kglab​ open source projects. Formerly: Director of Learning Group at O'Reilly Media; and Director of Community Evangelism at Databricks.Weidong YangWeidong Yang, Ph.D., is the founder and CEO of Kineviz, a San Francisco-based company that develops interactive visual analytics based solutions to address complex big data problems. His expertise spans Physics, Computer Science and Performing Art, with significant contributions to the semiconductor industry and quantum dot research at UC, Berkeley and Silicon Valley. Yang also leads Kinetech Arts, a 501(c) non-profit blending dance, science, and technology. An eloquent public speaker and performer, he holds 11 US patents, including the groundbreaking Diffraction-based Overlay technology, vital for sub-10-nm semiconductor production.// Related LinksWebsite: https://www.kineviz.com/Blog: https://medium.com/kinevizWebsite: https://derwen.ai/pacohttps://huggingface.co/pacoidhttps://github.com/ceterihttps://neo4j.com/developer-blog/entity-resolved-knowledge-graphs/~~~~~~~~ ✌️Connect With Us ✌️ ~~~~~~~Catch all episodes, blogs, newsletters, and more: https://go.mlops.community/TYExploreJoin our slack community [https://go.mlops.community/slack]Follow us on X/Twitter [@mlopscommunity](https://x.com/mlopscommunity) or [LinkedIn](https://go.mlops.community/linkedin)] Sign up for the next meetup: [https://go.mlops.community/register]MLOps Swag/Merch: [https://shop.mlops.community/]Connect with Demetrios on LinkedIn: /dpbrinkmConnect with Weidong on LinkedIn: /yangweidong/Connect with Paco on LinkedIn: /ceteri/

The combination of Brown Noise and Pink Noise offers a harmonious blend of soothing deep tones and balanced frequencies, creating a rich auditory environment perfect for relaxation and focus. Brown Noise, with its emphasis on low-frequency sounds, brings a grounding, almost earthy hum that resonates deeply, providing a calming and enveloping atmosphere. It's ideal for those seeking to unwind or drown out low-level background distractions. Pink Noise, in contrast, incorporates a balanced mixture of both high and low frequencies, creating a sound more natural and gentle compared to White Noise. It's often compared to the sound of rainfall or wind rustling through trees—soothing yet with a little more complexity than Brown Noise. Together, Brown Noise and Pink Noise work in perfect synergy, offering a peaceful and immersive experience that is ideal for promoting sleep, meditation, or concentration. ❗ ❗ To support this podcast and unlock all the ad-free and intro-free episodes, along with other benefits, SUBSCRIBE at ⁠⁠https://12hourwhitenoise.supercast.com⁠⁠ ❗ ❗Although there may be an ad or two at the very beginning of this free episode, you can rest assured that there will be no further interruptions or ads once the Sleep Sound begins

Warriors Head Coach Steve Kerr joined Willard & Dibs to discuss the Jonathan Kuminga situation, the upcoming playoff series against the Rockets, and why Jimmy Butler reminds him of Andre Iguodala.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.Managing allergic rhinitis requires realistic expectations and a strategic approach to medication. Though no treatment will completely eliminate symptoms, the right combination of therapies can significantly reduce discomfort and improve quality of life during allergy season.• Nasal corticosteroid sprays are first-line treatments that reduce inflammation in nasal passages• Proper technique matters: point spray toward outside of nostril and sniff gently "like smelling a flower"• Non-sedating antihistamines (Zyrtec, Claritin, Allegra) relieve itching, sneezing, and runny nose without drowsiness• Nasal antihistamine sprays provide targeted relief and can start working within minutes• Oral decongestants raise concerns about blood pressure and heart rate increases• Avoid nasal decongestant sprays (like Afrin) beyond 2-3 days to prevent rebound congestion• Combination therapies often work better than single medications• Consider allergen immunotherapy when standard treatments don't provide adequate reliefThank you for coming back to another episode of Your Checkup. Hopefully you were able to learn something for yourself, a loved one, or an allergic neighbor. Please check out our website, find us on Instagram, send us an email at yourcheckuppod@gmail.com and, most importantly, stay healthy my friends, until next time.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Brett Veach and Andy Reid legitimately may be the best GM/HC combination in all of sports ever. WE ARE LUCKY.

Both the Jaredits and Nephites were destroyed by secret combinations. Both Mormon and Moroni speak of secret combinations in our day. Modern revelation speaks of a very specific secret combination that has shown to have a devastating impact on those of us living in the latter-days.

Today we have Hassan back on the show. Hassan was one of our first guests for Huddle when he was working at Vercel, but since then, he's joined Together AI, one of the hottest companies in the world. They just raised a massive series B round. Hassan joins us to talk about Together AI, inference optimization and building AI applications. We touch on a bunch of topics like customer uses of AI, best practices for building apps, and what's next for Together AI. Timestamps 01:42 Opportunity at Together AI 04:26 Together raised a big round 06:06 Vision Behind Together AI 08:32 Problems in running Open Source Models 11:40 Speed For Inference 14:24 Fine Tuning 19:23 One or Two Models or a Combination of them 21:32 Serverless 22:21 Cold Start issues? 27:46 How much data do you need? 30:00 Balancing Reliability and Cost 34:07 How customers are using Together 42:36 Agent Recipes 47:03 Typical Mistakes buiilding AI apps

Michael Greenberg is a filmmaker who is preparing to make his first feature film and has a short film called The Combination in the 2025 Minneapolis St. Paul International Film Festival.  Learn more about Michael and his path as a filmmaker here in Minnesota and beyond.    CBS morning show 1996  https://youtu.be/ly9FZBTiXp0   Stratus Quo https://youtu.be/tb3vGkJaoyE?si=VCBEVt7iuVv_eFNl   The Combination Trailer  https://youtu.be/FOhT2vr0hg0   Linktree https://linktr.ee/filmandbeyond   www.filmandbeyond.com   Follow us on Instagram: @filmandbeyondpod Get episodes early and exclusive episodes with Patreon www.patreon.com/filmandbeyond YouTube www.youtube.com/@filmandbeyondpod  

Is it embarrassing if you met your partner via this one method? What’s the most audibly tortuous sound according to a London Magistrates court? This one actor is absolutely overrated according to Will Malcolm Turnball imitated Donald Trump, we’ve got him on to set the record straight! Andy Lee’s figured out White Lotus See omnystudio.com/listener for privacy information.

This week's final episode this season of the Pinning Combination podcast with The Gazette's K.J. Pilcher and Dick Briggs wraps up the Iowa college wrestling season.

A phase 3 study showed that combining pelabresib with ruxolitinib significantly improved spleen volume reduction and symptom relief in myelofibrosis patients compared to ruxolitinib alone, offering a promising new treatment option. Long-term use of gantenerumab may delay Alzheimer's dementia onset in individuals with inherited Alzheimer's, supporting the amyloid hypothesis and paving the way for future prevention strategies. Phase 3 trials demonstrated that povorcitinib, an oral JAK1 inhibitor, significantly improved clinical outcomes in adults with moderate to severe hidradenitis suppurativa, potentially offering a new treatment option. Research linked red meat allergy to bites from additional tick species, expanding the geographic risk area and highlighting the need for clinicians to consider this diagnosis in patients with unexplained allergic symptoms following tick bites.

In this research-packed episode, Dr. Scott Watier and Tommy Welling analyze groundbreaking findings from a network meta-analysis that evaluates the most effective combinations of fasting styles and exercise types for weight loss. The study's surprising conclusion reveals that alternate-day fasting paired with moderate-intensity continuous training significantly outperforms other approaches, scoring an impressive 88% effectiveness for weight loss and 93% for fat mass reduction. The hosts break down why this combination works so well—explaining how it enhances metabolic flexibility, improves insulin sensitivity, and promotes sustainable fat oxidation—while debunking common misconceptions about needing high-intensity workouts for optimal results. They provide practical guidance for implementing these evidence-based strategies, emphasizing that consistent moderate exercise (like zone 2 training) combined with strategic longer fasting windows delivers superior outcomes with better long-term adherence than traditional approaches. Whether you're just starting your fasting journey or looking to optimize your current routine, this episode offers clear, actionable insights backed by the latest scientific research. Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting! Resources and Downloads: SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! - December 2024 FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS! SLEEP GUIDE DIRECT DOWNLOAD DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE! Partner Links: Get your FREE BOX OF LMNT hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase here! Get 30% off a Keto-Mojo blood glucose and ketone monitor (discount shown at checkout)! Click here! Our Community: Let's continue the conversation. Click the link below to JOIN the Fasting For Life Community, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://storage.googleapis.com/msgsndr/6JyvZbS9DGozfkVmE452/media/67bf3a92ed60db2f5765f5e3.pdf

In this episode of Skincare Confidential, Dr. Patti Farris and Dr. Ellen Gendler discuss the resurgence of topical estrogen in skincare. In this engaging conversation, Ellen Gendler shares her years of experience and knowledge surrounding the use of topical estrogen creams. They explore the complexities of intrinsic aging, the clinical signs of estrogen deficient skin and the role of topical estrogen for preventing skin aging. They also discuss some of the concerns surrounding the use of topical estrogen and the potential role for selective estrogen receptor modulators or SERMs. Takeaways Topical estrogens have gained popularity for their potential skin benefits.Estrogen deficiency leads to various skin issues as we age.Topical estrogen can be beneficial when used correctly and in moderation.Concerns about systemic absorption of topical estrogens are prevalent.Case reports should be interpreted cautiously in the context of topical estrogen use.Different types of estrogens have varying effects on the skin.Studies show that topical estrogens can improve skin thickness and elasticity.Topical estrogens are not a substitute for other effective skincare treatments. Topical estrogen is more about prevention than reversal.Visible changes in skin care treatments are often immediate, unlike estrogen.The effectiveness of topical estrogen varies between sun-protected and photodamaged skin.Retinoids remain the gold standard in skin care for aging.Melasma exacerbation is a concern with topical estrogen, but evidence is limited.SERM compounds show promise but require more research.Combination approaches in skin care yield better results than relying on a single product.Online health products are proliferating, but caution is necessary.The importance of vetting sources for topical treatments cannot be overstated.Clinical judgment is essential in evaluating the effectiveness of skin care treatments. Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.

Craig Warnimont covers social media stocks. He likes Pinterest (PINS): though META is much bigger, he likes the company's financials and user engagement. He also talks about the potential impact of TikTok.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

The combination of Brown Noise, Pink Noise, and White Noise creates a rich and balanced auditory experience, blending the unique qualities of each to provide a soothing and immersive soundscape. Brown Noise, with its emphasis on deep, low-frequency sounds, creates a grounding, calming presence that resonates deeply. Pink Noise, with its mix of higher and lower frequencies, offers a gentle balance, both soothing and enhancing focus, providing a more natural sound similar to a quiet rain or distant thunder. White Noise, with its broad spectrum of frequencies, acts as a barrier, masking unwanted background sounds and creating a consistent, neutral hum that helps to promote relaxation and sleep. Together, these three types of noise work in harmony, creating an environment that fosters deep relaxation, concentration, and restful sleep.❗ ❗ To support this podcast and unlock all the ad-free and intro-free episodes, along with other benefits, SUBSCRIBE at ⁠⁠https://12hourwhitenoise.supercast.com⁠⁠ ❗ ❗Although there may be an ad or two at the very beginning of this free episode, you can rest assured that there will be no further interruptions or ads once the Sleep Sound begins

Combination Defense Course Teachhoops.com Coach Collins Coaching Store https://forms.gle/kQ8zyxgfqwUA3ChU7 Check out.  [Teachhoops.com](https://teachhoops.com/) 14 day Free Trial Youth Basketball Coaches Podcast Apple link: https://podcasts.apple.com/us/podcast/coaching-youth-hoops/id1619185302 Spotify link: https://open.spotify.com/show/0g8yYhAfztndxT1FZ4OI3A Funnel Down Defense Podcast https://podcasts.apple.com/us/podcast/funnel-down-defense/id1593734011 Want More Funnel Down Defense https://coachcollins.podia.com/funnel-down-defense [Facebook Group . Basketball Coaches](https://www.facebook.com/groups/basketballcoaches/) [Facebook Group . Basketball Drills](https://www.facebook.com/groups/321590381624013/) Want to Get a Question Answered? [ Leave a Question here](https://www.speakpipe.com/Teachhoops) Check out our other podcast [High School Hoops ](https://itunes.apple.com/us/podcast/high-school-hoops-coaching-high-school-basketball/id1441192866) Check out our Sponsors [HERE](https://drdishbasketball.com/) Mention Coach Unplugged and get 450 dollars off your next purchase basketball resources free basketball resources Coach Unplugged Basketball drills, basketball coach, basketball workouts, basketball dribbling drills,  ball handling drills, passing drills, shooting drills, basketball training equipment, basketball conditioning, fun basketball games, basketball jerseys, basketball shooting machine, basketball shot, basketball ball, basketball training, basketball camps, youth basketball, youth basketball leagues, basketball recruiting, basketball coaching jobs, basketball tryouts, basketball coach, youth basketball drills, The Basketball Podcast, How to Coach Basketball, Funnel Down Defense FDD Win the season Rule of 3 Offense Learn more about your ad choices. Visit podcastchoices.com/adchoices

Teachhoops.com FULL Season Access Coach Collins Coaching Store https://forms.gle/kQ8zyxgfqwUA3ChU7 Check out.  [Teachhoops.com](https://teachhoops.com/) 14 day Free Trial Youth Basketball Coaches Podcast Apple link: https://podcasts.apple.com/us/podcast/coaching-youth-hoops/id1619185302 Spotify link: https://open.spotify.com/show/0g8yYhAfztndxT1FZ4OI3A Funnel Down Defense Podcast https://podcasts.apple.com/us/podcast/funnel-down-defense/id1593734011 Want More Funnel Down Defense https://coachcollins.podia.com/funnel-down-defense [Facebook Group . Basketball Coaches](https://www.facebook.com/groups/basketballcoaches/) [Facebook Group . Basketball Drills](https://www.facebook.com/groups/321590381624013/) Want to Get a Question Answered? [ Leave a Question here](https://www.speakpipe.com/Teachhoops) Check out our other podcast [High School Hoops ](https://itunes.apple.com/us/podcast/high-school-hoops-coaching-high-school-basketball/id1441192866) Check out our Sponsors [HERE](https://drdishbasketball.com/) Mention Coach Unplugged and get 450 dollars off your next purchase basketball resources free basketball resources Coach Unplugged Basketball drills, basketball coach, basketball workouts, basketball dribbling drills,  ball handling drills, passing drills, shooting drills, basketball training equipment, basketball conditioning, fun basketball games, basketball jerseys, basketball shooting machine, basketball shot, basketball ball, basketball training, basketball camps, youth basketball, youth basketball leagues, basketball recruiting, basketball coaching jobs, basketball tryouts, basketball coach, youth basketball drills, The Basketball Podcast, How to Coach Basketball, Funnel Down Defense FDD Win the season Rule of 3 Offense Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Pinning Combination podcast with The Gazette's K.J. Pilcher and Dick Briggs previews the NCAA Division I Wrestling Championships, including first-round matchups for the University of Iowa, Iowa State, and the University of Northern Iowa. Listen to their championship picks. They also review the NCAA Division III and II and NAIA Women's Wrestling Championships.

The Gazette's K.J. Pilcher and Dick Briggs break down Iowa women's wrestling national title repeat, Grand View's NAIA title, and provide insights into the upcoming NCAA Division III and II Wrestling Championships on this week's episode of The Pinning Combination podcast.

The Pinning Combination podcast with The Gazette's K.J. Pilcher and Dick Briggs recaps the NCAA Division III Region VI tournament and Upper Iowa's performance at its D-II regional. They also break down the upcoming Big Ten, Big 12 and National Collegiate Women's Wrestling Championships.

Black cumin, also known as black seed oil, is an ancient remedy that has a multitude of surprising benefits! I was very impressed to find it improves fungal overgrowth, thyroid health, cholesterol and more. I'll dive into 10 health benefits of black cumin plus offer my recommended protocols.   Watch more videos like this

Want to Start or Grow a Successful Business? Schedule a FREE 13-Point Assessment with Clay Clark Today At: www.ThrivetimeShow.com   Join Clay Clark's Thrivetime Show Business Workshop!!! Learn Branding, Marketing, SEO, Sales, Workflow Design, Accounting & More. **Request Tickets & See Testimonials At: www.ThrivetimeShow.com  **Request Tickets Via Text At (918) 851-0102   See the Thousands of Success Stories and Millionaires That Clay Clark Has Helped to Produce HERE: https://www.thrivetimeshow.com/testimonials/ Download A Millionaire's Guide to Become Sustainably Rich: A Step-by-Step Guide to Become a Successful Money-Generating and Time-Freedom Creating Business HERE: www.ThrivetimeShow.com/Millionaire   See Thousands of Case Studies Today HERE: www.thrivetimeshow.com/does-it-work/